AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today added to its biologics manufacturing capability in the
US with the purchase of a high-tech biologics bulk manufacturing
facility from Amgen Inc. Over time, the LakeCentre facility, located in
Boulder, Colorado will increase manufacturing and production capacity to
support the company’s extensive portfolio of biologics medicines.

AstraZeneca plans to start staffing the facility immediately to support
refurbishment and infrastructure improvements. Once complete, the site
is expected to be operational and licensed for commercial production by
late 2017, providing for additional capacity within the company’s
biologics operations.

In the longer- term, this site could create up to 400 highly skilled
jobs, subject to relevant approvals by the local authorities. The
facility will eventually double the biologics manufacturing capacity in
the US to meet the needs of the maturing AstraZeneca pipeline. Currently
biologics make up 50 percent of the company’s pipeline with more than
120 ongoing programmes, including over 30 in clinical development.

Pam Cheng, Executive Vice-President, Operations and Information
Technology at AstraZeneca, said: “The addition of the Boulder facility
will support the progression of biotech drug candidates across our main
therapeutic areas as we continue to bring innovative new treatments to
patients. This site will play an important role in our future commercial
production and give AstraZeneca and MedImmune, our global biologics
research and development arm, the flexibility and capacity to meet the
needs of our rapidly growing biologics portfolio.”

The new facility in Boulder adds to the expansion of AstraZeneca’s
biologics manufacturing capabilities, following the planned biologics
manufacturing investment in Sweden, announced
in May
, and the expansion in Frederick, Maryland, announced
in November 2014

The financial details were not disclosed. This investment does not
impact AstraZeneca’s financial guidance for 2015.

– ENDS –


About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of cardiovascular,
metabolic, respiratory, inflammation, autoimmune, oncology, infection
and neuroscience diseases. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
For more information please visit:


Media Enquiries
Esra Erkal-Paler,
UK/Global, +44 20 7604 8030
Vanessa Rhodes, UK/Global, +44 20 7604
Ayesha Bharmal, UK/Global, +44 20 7604 8034
Birmingham, UK/Global, +44 20 7604 8120
Jacob Lund, Sweden, +46 8
553 260 20
Michele Meixell, US, +1 302-885-2677

Thomas Kudsk Larsen, Oncology, +44 20 7604
8199, +44 7818 524185
Eugenia Litz, RIA, +44 20 7604 8233, +44 7884
Nick Stone, CVMD, +44 20 7604 8236, +44 7717 618834
Marks, ING, +44 20 7604 8591, +44 7881 615764
Christer Gruvris, +44
20 7604 8126, +44 7827 836825
Lindsey Trickett,
Oncology, ING, +1 301-398-5118, +1 240-543-7970
Dial / Toll-Free,
+1 301-398-3251, +1 866-381-7277
Key: RIA – Respiratory,
Inflammation and Autoimmunity, CVMD – Cardiovascular and Metabolic
Disease, ING – Infection, Neuroscience and Gastrointestinal